Myoferlin (MYOF), as a member of the ferlin family, is a type II transmembrane protein with a single transmembrane domain at the carbon terminus. Studies have shown that MYOF is involved in pivotal physiological functions related to numerous cell membranes, such as extracellular secretion, endocytosis cycle, vesicle trafficking, membrane repair, membrane receptor recycling, and secreted protein efflux. Recently, the studies have also revealed that MYOF is overexpressed in a variety of cancers such as colorectal cancer, pancreatic cancer, breast cancer, melanoma, gastric cancer, and non-small-cell lung cancer. High expression of MYOF is associated with the high invasion of tumors and poor clinical prognosis. MYOF medicates the expression, secretion, and distribution of proteins, which were closely related to cancers, as well as the energy utilization of cancer cells, lipid metabolism and other physiological activities by regulating the physiological processes of membrane transport. In this short article, we briefly summarize the latest progress related to MYOF, indicating that small molecule inhibitors targeting the MYOF-C2D domain can selectively inhibit the proliferation and migration of cancer cells, and MYOF may be a promising target for the treatment of malignant tumors.

Myoferlin（MYOF）是Ferlin家族的成员，是II型跨膜蛋白，在碳末端具有单个跨膜结构域。研究表明，MYOF参与了与许多细胞膜有关的关键生理功能，例如细胞外分泌，胞吞作用周期，囊泡运输，膜修复，膜受体再循环和分泌的蛋白质外排。最近，研究还表明，MYOF在多种癌症（例如结直肠癌，胰腺癌，乳腺癌，黑色素瘤，胃癌和非小细胞肺癌）中过表达。MYOF的高表达与肿瘤的高度侵袭和临床预后不良有关。MYOF可治疗与癌症密切相关的蛋白质的表达，分泌和分布，通过调节膜运输的生理过程以及癌细胞的能量利用，脂质代谢和其他生理活动。在这篇简短的文章中，我们简要总结了与MYOF相关的最新进展，表明靶向MYOF-C2D结构域的小分子抑制剂可以选择性抑制癌细胞的增殖和迁移，而MYOF可能是治疗恶性肿瘤的有希望的靶标。